Plaintiffs Renew Schering Off-Label Marketing Claims

Law360, New York (May 6, 2010, 6:22 PM EDT) -- A group of health and welfare funds, third-party payors and individual consumers have revamped their putative class action accusing Schering-Plough Corp. of illegally marketing its drugs Intron-A and Temodar for off-label uses.

The plaintiffs filed their 168-page amended consolidated class action complaint Wednesday in the U.S. District Court for the District of New Jersey, repleading their Racketeer Influenced and Corrupt Organizations Act claims after a judge rejected their theory of injury in July.

After conducting additional discovery, the plaintiffs added to their complaint descriptions of Schering...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.